BioCentury | Feb 21, 2018
Distillery Therapeutics

Cardiovascular; hematology

INDICATION: Cardiovascular; hemophilia Mouse studies suggest BST1- and CD200-positive vascular endothelial cells could help treat vascular injury and hemophilia. In a mouse model of liver vascular injury, transplantation at the injury site of vascular endothelial...
BioCentury | Feb 13, 2018
Preclinical News

Vascular endothelial stem cells could enable regenerative therapy

In a study published in Cell Stem Cell , researchers at Osaka University and colleagues discovered a population of vascular endothelial cells that could be used as a regenerative therapy for vascular injury and hemophilia. The...
BioCentury | Jul 28, 2017
Company News

Alexion announces pipeline restructuring

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) restructured its pipeline to focus on its core complement inhibitor franchise and its approved rare disease products, dropping early stage rare disease partnerships with Moderna Therapeutics Inc. (Cambridge, Mass.), Blueprint Medicines...
BioCentury | Jul 28, 2017
Company News

Alexion refocusing on complement cascade

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) restructured its pipeline to focus on its core complement inhibitor franchise and its approved rare disease products, dropping early stage rare disease partnerships with Moderna Therapeutics Inc. (Cambridge, Mass.), Blueprint Medicines...
BioCentury | Oct 24, 2016
Clinical News

Leukemia & Lymphoma Society pipeline update

The Leukemia & Lymphoma Society launched the collaborative Phase IIa/IIb Beat AML trial, which will evaluate multiple candidates to treat first-line acute myelogenous leukemia (AML). The trial will enroll newly diagnosed AML patients ages >=60....
BioCentury | Oct 24, 2016
Product Development

A new BEAT for AML

With the first collaborative, multidrug trial in a blood cancer, The Leukemia & Lymphoma Society aims to dramatically alter the 40-year-old diagnosis and treatment paradigm in first-line acute myelogenous leukemia, and to create a virtuous...
BioCentury | Oct 18, 2016
Top Story

LLS launches collaborative AML trial

On Tuesday, the Leukemia & Lymphoma Society launched the collaborative Phase IIa/IIb Beat AML trial, which will evaluate multiple candidates to treat first-line acute myelogenous leukemia. The trial will enroll newly diagnosed AML patients aged...
BioCentury | Nov 10, 2011
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer CD200 In vitro and mouse studies suggest anti-CD200 antibodies could help treat CD200-negative tumors, in addition to CD200-positive tumors. In a mouse model of...
BioCentury | Aug 25, 2011
Tools & Techniques

Taking out teratoma potential

Researchers at the Stanford University School of Medicine have developed an approach for separating human pluripotent stem cells from teratoma-forming cells in culture. 1 The group thinks the procedure could help allay tumorigenicity concerns associated...
BioCentury | Feb 14, 2011
Strategy

Alexion's expansions

Alexion Pharmaceuticals Inc. last week laid out its plans for keeping up the momentum that has resulted in a doubling of market cap in the past year, from $4.1 billion on Feb. 12, 2010, to...
Items per page:
1 - 10 of 16